gamma-aminobutyric acid type A receptor subunit alpha1Genealiases: DEE19 · ECA4 · EIEE19 · EJM · EJM5
Q-omics provides the consensus-scored GABRA1 profile across patient tissues and cancer cell-line models. GABRA1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GABRA1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, GABRA1 protein abundance shows 17,342 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, COAD, and GBM as cancer lineages where GABRA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRA1 survival associations across molecular data types. GABRA1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRA1 RNA expression–survival associations across cancer types. High GABRA1 expression shows unfavorable associations in BLCA, SCLC, UVM and ACC, but favorable associations in PAAD and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GABRA1 RNA expression.
This table summarizes GABRA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GABRA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRA1 shows lower tumor expression in COAD, STAD, LUAD and ESCA and higher tumor expression in THCA and BRCA. The COAD box plot shows higher GABRA1 RNA expression in normal versus tumor tissue (log2 FC = −0.021, t-test p < 0.001).
This table shows molecular features associated with GABRA1 in patient tissues and cancer cell lines. In patient samples, GABRA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
